ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

secukinumab

Also written as “Secukinumab”, “AIN457” and “Secukinumab 300 mg”.

Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Spondylitis, Ankylosing · Arthritis, Rheumatoid · Hidradenitis Suppurativa, led by 3 companies.

Drug pageSecukinumab: every studyAll 177 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jul 12, 2015128 company-led studies, 4 open or runningNext primary completion: Feb 8, 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only1254 open or runningphase 4since Jul 12, 2015Dec 21, 2007Feb 8, 2028phase 4 · NCT05622708
Taizhou Mabtech Pharmaceuticalits history only20 open or runningphase 1since Jan 29, 2023Jan 29, 2023none ahead
Johnson & Johnson10 open or runningphase 1since Oct 13, 2020Oct 13, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 13, 2020First study: phase 1 study in HealthyFirst studyNCT04589026 · 12 enrolled · Belgium

TargetBeta

IL17A →read by rule
“A recombinant human immunoglobulin G1 (IgG1) monoclonal antibody against the pro-inflammatory cytokine interleukin 17A (IL-17A; IL-17), ”NCIt, by rule
“Interleukin 17A inhibitor”ChEMBL 37, by rule

Other programs on IL17A

ProgramCompanyFurthest phaseStudies
ixekizumabruleEli Lillyphase 438
vunakizumabruleJiangsu HengRui Medicinephase 417
bimekizumabruleUCBphase 343
sonelokimabrulemoonlake-immunotherapeutics-agphase 312
simepdekinraEli Lillyphase 27
tibulizumabruleEli Lillyphase 25
SCT650CruleSinocelltech Groupphase 23
UA026ruleusynova-pharmaceuticals-ltdphase 11

Studies

The one study Johnson & Johnson leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04589026Healthy · Belgium1CompletedMay 6, 202112

How it is read

Names in the registry

  • “Secukinumab”, 47 entries
  • “AIN457”, 38 entries
  • “secukinumab”, 7 entries
  • “Secukinumab 300 mg”, 6 entries
  • “Secukinumab (AIN457)”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.